Has Sana Akbar received payments from drug or device companies?

Yes. Drug and device makers reported $2,717 in general payments to Sana Akbar across 129 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sana Akbar did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sana Akbar come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sana Akbar

Endocrinology, Diabetes & Metabolism · Greenbelt, MDNPI 1922448604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total.

$2,717in general payments, 2019–2025

Across 129 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$674
Lilly USA, LLC$347
Insulet Corporation$272
Xeris Pharmaceuticals, Inc.$194
Amneal Pharmaceuticals LLC$166
Sanofi-aventis U.S. LLC$161
plus $904 from 17 others

What the payments were for

Food & beverage$2,70399%
Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	36	$674
Lilly USA, LLC	14	$347
Insulet Corporation	7	$272
Xeris Pharmaceuticals, Inc.	9	$194
Amneal Pharmaceuticals LLC	9	$166
Sanofi-aventis U.S. LLC	9	$161
Amgen	6	$109
Bayer	4	$102
Antares Pharma, Inc.	4	$95
Abbott	4	$77
Medtronic	4	$69
Mannkind Corporation	2	$65
Tandem Diabetes Care, Inc.	3	$62
Corcept Therapeutics	3	$56
Merck	3	$52
Dexcom, Inc.	2	$50
BETA Bionics, Inc.	2	$35
IBSA Pharma Inc.	2	$33
Acerus Pharmaceuticals Corporation	2	$28
BD	1	$22
AbbVie	1	$18
Boehringer Ingelheim	1	$16
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Omnipod$146
RYBELSUS$118

How this compares

$2,717 in reported general payments places this provider in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Other endocrinology, diabetes & metabolism in Greenbelt

Irfan KhanGreenbelt$11K
Sabreen AhmedGreenbelt$10K
Surosh NazeerGreenbelt$9K
Daniel GozziSuitland$1.2M
Martin SarkarFrederick$1.1M
Nicholas ArgentoLaurel$1.1M
Romeu AzevedoCamp Springs$987K
David BrownRockville$497K
Philip LevinBaltimore$489K
Helena RodbardRockville$468K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →